HighTower Advisors
LCTX icon

HighTower Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

HighTower Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Hold
99,870
– – ﹤0.01% 3618
2026
Q1 		$158K Buy
99,870
+1,500
+2% +$2.53K ﹤0.01% 3554
2025
Q4 		$164K Hold
98,370
– – ﹤0.01% 3419
2025
Q3 		$166K Buy
98,370
+40,664
+70% +$48.1K ﹤0.01% 3423
2025
Q2 		$52.4K Hold
57,706
– – ﹤0.01% 3544
2025
Q1 		$26.1K Hold
57,706
– – ﹤0.01% 3502
2024
Q4 		$29K Buy
57,706
+19,100
+49% +$14K ﹤0.01% 3509
2024
Q3 		$35K Sell
38,606
-17,065
-31% -$15.8K ﹤0.01% 3455
2024
Q2 		$56K Sell
55,671
-8,300
-13% -$9.17K ﹤0.01% 3293
2024
Q1 		$95K Buy
63,971
+9,900
+18% +$11.2K ﹤0.01% 3161
2023
Q4 		$59K Hold
54,071
– – ﹤0.01% 3277
2023
Q3 		$64K Buy
54,071
+19,955
+58% +$27.1K ﹤0.01% 3189
2023
Q2 		$48K Sell
34,116
-16,000
-32% -$22.1K ﹤0.01% 3168
2023
Q1 		$75K Buy
50,116
+16,000
+47% +$22.3K ﹤0.01% 2991
2022
Q4 		$40K Buy
34,116
+700
+2% +$882 ﹤0.01% 3065
2022
Q3 		$37K Hold
33,416
– – ﹤0.01% 2918
2022
Q2 		$53K Hold
33,416
– – ﹤0.01% 2900
2022
Q1 		$51K Hold
33,416
– – ﹤0.01% 3067
2021
Q4 		$82K Buy
33,416
+100
+0.3% +$234 ﹤0.01% 2956
2021
Q3 		$84K Buy
33,316
+17,000
+104% +$43.6K ﹤0.01% 2866
2021
Q2 		$46K Hold
16,316
– – ﹤0.01% 2900
2021
Q1 		$38K Hold
16,316
– – ﹤0.01% 2858
2020
Q4 		$28K Buy
+16,316
New +$22.8K ﹤0.01% 2458

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HighTower Advisors's LCTX Position: Q2 2026 in Review

HighTower Advisors held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 99,870 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #3618.

HighTower Advisors first reported a position in LCTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $166K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • HighTower Advisors held 99,870 shares of Lineage Cell Therapeutics worth $131K as of Q2 2026.
  • HighTower Advisors left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3618 holding.
  • HighTower Advisors first reported a position in Lineage Cell Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • HighTower Advisors's Lineage Cell Therapeutics position peaked at $166K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.